Takafumi Koyama

ORCID: 0000-0002-1676-7578 · 2 papers in corpus

nonrandomized-trial 2024

Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers

Journal for immunotherapy of cancer ·doi:10.1136/jitc-2024-009262

BACKGROUND: Immunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to imm…

lab-animal 1997

Effects of conjugated estrogens with or without medroxyprogesterone acetate on mammary carcinogenesis, uterine adenomyosis and femur in mice

Acta anatomica ·doi:10.1159/000147985

Although combined hormone replacement therapy using estrogens and progestins reduces the risk of endometrial cancer in postmenopausal women, it has been unclear whether the combined therapy is associated with an alteration of the risk of ma…